Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

• Damon Bass,
• Regina Kurrasch,
• Yin Su,
• Jie Zheng,
• Yang Li,
• Guochun Wang,
• Fengchun Zhang,
• David A Roth,
• Jieruo Gu,
• Jenny Lowe,
• Myron Chu,
• Paula Curtis,
• Kathleen DeRose,
• Paige Meizlik,
• Mingjun Wang,
• Xingfu Li

Affiliations

Damon Bass

GlaxoSmithKline, Collegeville, Pennsylvania, USA

Regina Kurrasch

GlaxoSmithKline, Collegeville, Pennsylvania, USA

Yin Su

1 Department of Rheumatology and Immunology, Peking University People`s Hospital, Beijing, China

Jie Zheng

3 Clinical Research Center, The First Affiliated Hospital of Xi`an Jiaotong University, Xi`an, China

Yang Li

Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China

Guochun Wang

4 Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China

Fengchun Zhang

Department of Rheumatology, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China

David A Roth

Research & Development, GlaxoSmithKline, Collegeville, South Carolina, USA

Jieruo Gu

Rheumatology Department, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Jenny Lowe

GlaxoSmithKline, Brentford, Middlesex, UK

Myron Chu

GlaxoSmithKline, Collegeville, Pennsylvania, USA

Paula Curtis

GlaxoSmithKline, Brentford, Middlesex, UK

Kathleen DeRose

GlaxoSmithKline, Collegeville, Pennsylvania, USA

Paige Meizlik

GlaxoSmithKline, Collegeville, Pennsylvania, USA

Mingjun Wang

Department of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China

Xingfu Li

Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, China